Explore News
-
70% of Patients Achieve Weight Loss with Semaglutide Post-Surgery
New research reveals that semaglutide, a GLP-1 receptor agonist, significantly aids weight loss in patients…
-
Retatrutide Yields 28% Weight Loss in 80 Weeks
Eli Lilly’s experimental drug retatrutide led to unprecedented weight reduction in trial participants, signaling a…
-
How the Pill Form of Wegovy Could Transform Weight Loss Care
The European Medicines Agency’s green light marks a pivotal shift in obesity treatment, offering millions…
-
How a Father’s Obesity Affects His Children’s Metabolism
A groundbreaking study uncovers the epigenetic mechanism through which obese fathers transmit metabolic dysfunction to…
-
AI Reveals 37% Increase in Nerve Fiber Density in Obese Mice
A new deep-learning platform, MouseMapper, exposes previously invisible structural changes in nerves linked to diet-indu
-
AI Atlas Reveals Hidden Whole-Body Damage Caused by Obesity
A groundbreaking AI-powered whole-body mapping study uncovers extensive, previously invisible damage caused by obesity,
-
78% of Users Report Reduced Food Cravings on GLP-1s
New research illuminates how drugs like Ozempic and Mounjaro suppress ‘food noise,’ transforming the way…
-
New Oral Delivery Method Boosts GLP-1 Drug Efficacy by 80%
A novel delivery system from Duke University allows patients to take GLP-1 medications orally with…
-
Ozempic Cuts Blood Pressure by 5 Points in New Study
A growing body of evidence suggests that GLP-1 receptor agonists, originally developed for type 2…
